[Skip to Navigation]
Sign In
Comment & Response
August 13, 2020

Targeted Intraoperative Radiotherapy for Early Breast Cancer

Author Affiliations
  • 1Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
  • 2Alpert Medical School of Brown University, Lifespan Cancer Institute, Providence, Rhode Island
  • 321st Century Oncology, Farmington Hills, Michigan
JAMA Oncol. 2020;6(10):1635-1636. doi:10.1001/jamaoncol.2020.2713

To the Editor We read with interest the report on the long-term recurrence and survival outcomes after treatment with delayed second-procedure targeted intraoperative radiotherapy (IORT) vs whole-breast radiotherapy by Vaidya et al.1 Since the publication of 5-year outcomes from the TARGIT-A trial,2 the oncology community has awaited long-term outcomes from the study to evaluate the utility of IORT for early breast cancer. The recent publication of the delayed-treatment cohort of patients from the TARGIT-A trial has now provided additional information. The study found that 5-year local recurrence rates were 3.96% with delayed second-procedure IORT compared with 1.05% with whole-breast irradiation (WBI), which was not noninferior. No difference in mastectomy-free survival, distant disease-free survival, or overall survival was noted.1

Add or change institution